WSAAI 2022 59th Annual Scientific Session
This year's meeting will cover novel diagnostics and therapeutics involved in severe asthma, the prevention of food allergies as well as cutting edge treatments for food allergies, address the skin as the largest immune organ and discuss other immunodeficiency and hypersensitivity disease.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and Western Society of Allergy, Asthma and Immunology (WSAAI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.”
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 20 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from CSL Behring, Grifols, Genentech, Optinose, AstraZeneca
Allergists and Allied Health Providers
Upon completion of this activity, participants should be able to:
- Recognize the different monoclonal antibody therapies for severe asthma and future agents in the drug pipeline
- Learn how gastroenterologists approach patients with mast cell disorders
- Recognize the current and potential roles of biologics to treat chronic rhinosinusitis
- Follow a world-expert in primary immunodeficiencies on how she approaches the diagnosis and treatment of PIDD
- 20.00 AMA PRA Category 1 Credit™
- 20.00 Attendance
- 20.00 CBRN